STRIDE - STimulating Immune Response In aDvanced brEast Cancer
Status:
Terminated
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the
indication of breast cancer following the clinical hold on the investigational new drug
application for tecemotide (L-BLP25).